iotaMotion

iotaMotion operates in the medical-device and surgical-robotics segment, with a focused application: cochlear implant electrode insertion. Its iotaSOFT system is designed to control insertion speed and acceleration, aiming to reduce procedural variability and limit trauma to the cochlea. This specialization distinguishes its stated product scope from general-purpose surgical robotics, while its open-platform approach is intended to fit cochlear implant workflows. The company’s reported adoption provides a measure of commercial traction: it announced use at more than 35 U.S. cochlear implant centers in January 2026, following an install base of 25 centers reported in January 2025, and surpassed 1,000 clinical procedures in September 2025. Its categories span medical devices, robotics, biotechnology and medical technology, and it remains a privately held company with a Series B as its latest recorded funding type. The available company comparisons do not identify valid peer companies—the listed entries repeat iotaMotion itself—so naming direct competitors or claiming market-share leadership would not be supportable.

iotaMotion’s financing and adoption milestones suggest a development path from early funding toward broader clinical deployment. Its recorded financing includes a $2 million Seed round in 2017, a $12 million Series A in 2023 led by Research Corporation Technologies, and a $6,431,502 Series B announced on Jan 28, 2025. Structured funding information totals $31,346,464 across 11 reported rounds, although only 10 individual round entries are detailed. The January 2025 announcement paired financing with an install base of 25 centers. By Sep 25, 2025, the company reported more than 1,000 procedures using iotaSOFT; by Jan 14, 2026, more than 35 U.S. centers were using the system, including Cincinnati Children’s Hospital as its first dedicated pediatric center. Expanded FDA clearance for pediatric use in January 2026 widened the stated clinical scope, while patent announcements in June 2025 and March 2026 added intellectual-property milestones.